Rituximab

Exacerbation of anti-MOG positive neuromyelitis optica spectrum disorders in the form of tumefactive demyelination lesions following off-label treatment: case report

    Reactions Weekly volume 1842, page324(2021)Cite this article

    This is a preview of subscription content, access via your institution.

    Access options

    Buy single article

    Instant access to the full article PDF.

    US$ 49.95

    Tax calculation will be finalised during checkout.

    Reference

    1. Breza M, et al. Tumefactive demyelination following rituximab in an anti-MOG positive nmosd patient: Evidence of T-cell and NK-cell involvement. Multiple Sclerosis Journal 26 (Suppl.): 481 (plus poster) abstr. P0760, No. 3, Dec 2020. Available from: URL: http://doi.org/10.1177/1352458520974937 [abstract]

    Download references

    Rights and permissions

    Reprints and Permissions

    About this article

    Verify currency and authenticity via CrossMark

    Cite this article

    Rituximab. Reactions Weekly 1842, 324 (2021). https://doi.org/10.1007/s40278-021-91060-3

    Download citation